{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:14:30Z","timestamp":1789535670699,"version":"build-2803163510"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02734-1","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:04:57Z","timestamp":1771308297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decoding the archipelago: single-cell biomarkers rechart the molecular geography of acute myeloid leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"Fengjie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed Soleimani","family":"Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5898-591X","authenticated-orcid":false,"given":"Farzaneh","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"7834","key":"2734_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles LA, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020;587(7834):477\u201382.","journal-title":"Nature"},{"issue":"23","key":"2734_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"2734_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, et al. Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265\u2013e128124.","journal-title":"Cell"},{"issue":"1","key":"2734_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10020-025-01085-w","volume":"31","author":"Z Khosroabadi","year":"2025","unstructured":"Khosroabadi Z, et al. Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives. Mol Med. 2025;31(1):33.","journal-title":"Mol Med"},{"issue":"4","key":"2734_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood.2021014670","volume":"141","author":"A Ediriwickrema","year":"2023","unstructured":"Ediriwickrema A, Gentles AJ, Majeti R. Single-cell genomics in AML: extending the frontiers of AML research. Blood. 2023;141(4):345\u201355.","journal-title":"Blood"},{"issue":"2","key":"2734_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/10428194.2024.2422833","volume":"66","author":"N Lecornec","year":"2025","unstructured":"Lecornec N, Duchmann M, Itzykson R. Single-cell sequencing applications in acute myeloid leukemia. Leuk Lymphoma. 2025;66(2):175\u201389.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2734_CR7","doi-asserted-by":"publisher","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","volume":"15","author":"R Wegmann","year":"2024","unstructured":"Wegmann R, et al. Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia. Nat Commun. 2024;15(1):9402.","journal-title":"Nat Commun"},{"key":"2734_CR8","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368(22):2059\u201374.","DOI":"10.1056\/NEJMoa1301689"},{"key":"2734_CR9","doi-asserted-by":"publisher","first-page":"1494106","DOI":"10.3389\/fimmu.2024.1494106","volume":"15","author":"G He","year":"2024","unstructured":"He G, et al. Single-cell transcriptomics reveals heterogeneity and prognostic markers of myeloid precursor cells in acute myeloid leukemia. Front Immunol. 2024;15:1494106.","journal-title":"Front Immunol"},{"issue":"1","key":"2734_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12967-025-06659-0","volume":"23","author":"X-P Li","year":"2025","unstructured":"Li X-P, et al. A multi-omic single-cell landscape reveals transcription and epigenetic regulatory features of t(8;21) AML. J Translational Med. 2025;23(1):816.","journal-title":"J Translational Med"},{"key":"2734_CR11","doi-asserted-by":"publisher","first-page":"100023","DOI":"10.1016\/j.amolm.2023.100023","volume":"2","author":"A Quattrocchi","year":"2023","unstructured":"Quattrocchi A, et al. Biomarkers in acute myeloid leukemia: from state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target. Aspects Mol Med. 2023;2:100023.","journal-title":"Aspects Mol Med"},{"issue":"9","key":"2734_CR12","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13(9):2032\u201349.","journal-title":"Cancer Discov"},{"issue":"1","key":"2734_CR13","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang B, et al. Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun. 2024;15(1):1821.","journal-title":"Nat Commun"},{"issue":"1","key":"2734_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-024-00479-6","volume":"13","author":"J Liu","year":"2024","unstructured":"Liu J, et al. Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance. Exp Hematol Oncol. 2024;13(1):12.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2734_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, et al. A cellular hierarchy framework for Understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28(6):1212\u201323.","journal-title":"Nat Med"},{"issue":"7","key":"2734_CR16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41587-022-01210-8","volume":"40","author":"TE Miller","year":"2022","unstructured":"Miller TE, et al. Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations. Nat Biotechnol. 2022;40(7):1030\u20134.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2734_CR17","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41467-021-21650-1","volume":"12","author":"L Velten","year":"2021","unstructured":"Velten L, et al. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nat Commun. 2021;12(1):1366.","journal-title":"Nat Commun"},{"issue":"1","key":"2734_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, et al. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Experimental Med. 2025;25(1):230.","journal-title":"Clin Experimental Med"},{"key":"2734_CR19","doi-asserted-by":"publisher","first-page":"104916","DOI":"10.1016\/j.critrevonc.2025.104916","volume":"215","author":"M Huang","year":"2025","unstructured":"Huang M, et al. Epigenetic mechanisms and next-gen editing platforms in hematology: from molecular basis to therapeutic frontiers. Crit Rev Oncol\/Hematol. 2025;215:104916.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"2734_CR20","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1):5327.","journal-title":"Nat Commun"},{"key":"2734_CR21","doi-asserted-by":"publisher","first-page":"104577","DOI":"10.1016\/j.exphem.2024.104577","volume":"137","author":"A Zeng","year":"2024","unstructured":"Zeng A, et al. 2020 \u2013 precise single-cell transcriptomic mapping of normal and leukemic cell states reveals unconventional lineage priming in acute myeloid leukemia. Exp Hematol. 2024;137:104577.","journal-title":"Exp Hematol"},{"issue":"1","key":"2734_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo R, et al. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res. 2021;9(1):15.","journal-title":"Biomark Res"},{"issue":"1","key":"2734_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A, et al. Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Experimental Med. 2025;25(1):73.","journal-title":"Clin Experimental Med"},{"issue":"11","key":"2734_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083\u20136.","journal-title":"Nat Methods"},{"issue":"9","key":"2734_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41592-023-01938-4","volume":"20","author":"C Bravo Gonz\u00e1lez-Blas","year":"2023","unstructured":"Bravo Gonz\u00e1lez-Blas C, et al. SCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks. Nat Methods. 2023;20(9):1355\u201367.","journal-title":"Nat Methods"},{"issue":"1","key":"2734_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s44337-025-00515-2","volume":"2","author":"X Sun","year":"2025","unstructured":"Sun X, Fu R. Integrated multi-omics profiling develops a prognostic model based on Endoplasmic reticulum stress in acute myeloid leukemia. Discover Med. 2025;2(1):273.","journal-title":"Discover Med"},{"issue":"7","key":"2734_CR27","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/imcb.12456","volume":"99","author":"FM Marsh-Wakefield","year":"2021","unstructured":"Marsh-Wakefield FM, et al. Making the most of high-dimensional cytometry data. Immunol Cell Biol. 2021;99(7):680\u201396.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"2734_CR28","doi-asserted-by":"publisher","first-page":"10702","DOI":"10.1038\/s41467-024-55179-w","volume":"15","author":"C Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger C, et al. Unveiling the power of high-dimensional cytometry data with CyCONDOR. Nat Commun. 2024;15(1):10702.","journal-title":"Nat Commun"},{"issue":"10","key":"2734_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cyto.a.22992","volume":"89","author":"RR Montgomery","year":"2016","unstructured":"Montgomery RR. High standards for high dimensional investigations. Cytometry A. 2016;89(10):886\u20138.","journal-title":"Cytometry A"},{"key":"2734_CR30","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/pore.2024.1611747","volume":"30","author":"A M\u00e1rton","year":"2024","unstructured":"M\u00e1rton A, et al. The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia. Pathol Oncol Res. 2024;30:2024.","journal-title":"Pathol Oncol Res"},{"issue":"7633","key":"2734_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"24","key":"2734_CR32","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1001\/jama.2010.1862","volume":"304","author":"AJ Gentles","year":"2010","unstructured":"Gentles AJ, et al. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010;304(24):2706\u201315.","journal-title":"JAMA"},{"issue":"1","key":"2734_CR33","doi-asserted-by":"publisher","first-page":"31612","DOI":"10.1038\/s41598-025-17288-4","volume":"15","author":"F Wang","year":"2025","unstructured":"Wang F, et al. Signature of leukemia stem cell death pattern predicts prognosis and therapeutic response of acute myeloid leukemia patients. Sci Rep. 2025;15(1):31612.","journal-title":"Sci Rep"},{"issue":"75","key":"2734_CR34","doi-asserted-by":"publisher","first-page":"34056","DOI":"10.18632\/oncotarget.26118","volume":"9","author":"AM Zahran","year":"2018","unstructured":"Zahran AM, et al. Survival outcomes of CD34(+)CD38(-)LSCs and their expression of CD123 in adult AML patients. Oncotarget. 2018;9(75):34056\u201365.","journal-title":"Oncotarget"},{"issue":"33","key":"2734_CR35","doi-asserted-by":"publisher","first-page":"2308711","DOI":"10.1002\/advs.202308711","volume":"11","author":"F Chen","year":"2024","unstructured":"Chen F, et al. VEGF-FGF signaling activates quiescent CD63\u2009+\u2009Liver stem cells to proliferate and differentiate. Adv Sci. 2024;11(33):2308711.","journal-title":"Adv Sci"},{"issue":"1","key":"2734_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41392-025-02340-6","volume":"10","author":"C Galassi","year":"2025","unstructured":"Galassi C, et al. Epigenetic regulation of cancer stemness. Signal Transduct Target Ther. 2025;10(1):243.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2734_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s13287-024-04008-4","volume":"15","author":"Y Xinyi","year":"2024","unstructured":"Xinyi Y, et al. Emerging insights into epigenetics and hematopoietic stem cell trafficking in age-related hematological malignancies. Stem Cell Res Ther. 2024;15(1):401.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"2734_CR38","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41375-025-02539-0","volume":"39","author":"T Reuvekamp","year":"2025","unstructured":"Reuvekamp T, et al. CD34\u2009+\u2009CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents. Leukemia. 2025;39(4):972\u20135.","journal-title":"Leukemia"},{"key":"2734_CR39","doi-asserted-by":"crossref","unstructured":"Mitchell K, Steidl U. Targeting immunophenotypic markers on leukemic stem cells: how lessons from current approaches and advances in the leukemia stem cell (LSC) model can inform better strategies for treating acute myeloid leukemia (AML). Cold Spring Harb Perspect Med. 2020;10(1):a036251.","DOI":"10.1101\/cshperspect.a036251"},{"issue":"9","key":"2734_CR40","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1038\/bcj.2011.35","volume":"1","author":"D Wisniewski","year":"2011","unstructured":"Wisniewski D, et al. Further phenotypic characterization of the primitive lineage\u2013 CD34\u2009+\u2009CD38\u2013CD90\u2009+\u2009CD45RA\u2013 hematopoietic stem cell\/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia. Blood Cancer J. 2011;1(9):e36\u201336.","journal-title":"Blood Cancer J"},{"key":"2734_CR41","doi-asserted-by":"crossref","unstructured":"Vergez F, et al. CD34(+)CD38(-)CD123(+) leukemic stem cell frequency predicts outcome in older acute myeloid leukemia patients treated by intensive chemotherapy but not hypomethylating agents. Cancers (Basel). 2020;12(5):1174.","DOI":"10.3390\/cancers12051174"},{"issue":"3","key":"2734_CR42","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/jha2.466","volume":"3","author":"DDH Kim","year":"2022","unstructured":"Kim DDH, et al. The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic Haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem. 2022;3(3):873\u201384.","journal-title":"EJHaem"},{"issue":"3","key":"2734_CR43","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/bloodadvances.2021005741","volume":"6","author":"SWK Ng","year":"2022","unstructured":"Ng SWK, et al. A clinical laboratory\u2013developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Blood Adv. 2022;6(3):1064\u201373.","journal-title":"Blood Adv"},{"issue":"5","key":"2734_CR44","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"issue":"1","key":"2734_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64\u201374.","journal-title":"Leukemia"},{"issue":"2","key":"2734_CR46","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","volume":"17","author":"F Li","year":"2018","unstructured":"Li F, et al. Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia. Mol Cancer Ther. 2018;17(2):554\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2734_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"14","key":"2734_CR48","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","volume":"2","author":"Y-P Jiang","year":"2018","unstructured":"Jiang Y-P, et al. CLT030, a leukemic stem cell\u2013targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2(14):1738\u201349.","journal-title":"Blood Adv"},{"issue":"6","key":"2734_CR49","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12185-013-1433-6","volume":"98","author":"Y Kikushige","year":"2013","unstructured":"Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627\u201333.","journal-title":"Int J Hematol"},{"issue":"3","key":"2734_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, et al. A TIM-3\/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341\u201352.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2734_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/jjco\/hyad027","volume":"53","author":"N Asada","year":"2023","unstructured":"Asada N, et al. Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan. Jpn J Clin Oncol. 2023;53(7):595\u2013603.","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"2734_CR52","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"D DiNardo Courtney","year":"2020","unstructured":"DiNardo Courtney D, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"2734_CR53","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/ejh.14404","volume":"114","author":"B Ghimire","year":"2025","unstructured":"Ghimire B, Zimmer M, Donthireddy V. TP53-Mutated acute myeloid leukemia: review of treatment and challenges. Eur J Haematol. 2025;114(6):924\u201337.","journal-title":"Eur J Haematol"},{"key":"2734_CR54","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Medina C, et al. Biomarkers of response to venetoclax therapy in acute myeloid leukemia. Int J Mol Sci. 2024;25(3):1421.","DOI":"10.3390\/ijms25031421"},{"issue":"1","key":"2734_CR55","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-022-02783-y","volume":"23","author":"Z Liu","year":"2022","unstructured":"Liu Z, Sun D, Wang C. Evaluation of cell-cell interaction methods by integrating single-cell RNA sequencing data with Spatial information. Genome Biol. 2022;23(1):218.","journal-title":"Genome Biol"},{"issue":"1","key":"2734_CR56","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-024-01888-z","volume":"9","author":"J Su","year":"2024","unstructured":"Su J, et al. Cell\u2013cell communication: new insights and clinical implications. Signal Transduct Target Therapy. 2024;9(1):196.","journal-title":"Signal Transduct Target Therapy"},{"key":"2734_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.coisb.2021.03.007","volume":"26","author":"AA Almet","year":"2021","unstructured":"Almet AA, et al. The landscape of cell-cell communication through single-cell transcriptomics. Curr Opin Syst Biol. 2021;26:12\u201323.","journal-title":"Curr Opin Syst Biol"},{"issue":"1","key":"2734_CR58","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, et al. Inference and analysis of cell-cell communication using cellchat. Nat Commun. 2021;12(1):1088.","journal-title":"Nat Commun"},{"key":"2734_CR59","doi-asserted-by":"crossref","unstructured":"Bridges, K. and Miller-Jensen, K. Mapping and validation of scRNA-seq-derived cell-cell communication networks in the tumor microenvironment. Front immunol. 2022;13:885267.","DOI":"10.3389\/fimmu.2022.885267"},{"issue":"2","key":"2734_CR60","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41592-022-01728-4","volume":"20","author":"Z Cang","year":"2023","unstructured":"Cang Z, et al. Screening cell-cell communication in spatial transcriptomics via collective optimal transport. Nat Methods. 2023;20(2):218\u201328.","journal-title":"Nat Methods"},{"key":"2734_CR61","doi-asserted-by":"crossref","unstructured":"Shao X, et al. New avenues for systematically inferring cell-cell communication: through single-cell transcriptomics data. Protein Cell. 2020;11:866\u201380.","DOI":"10.1007\/s13238-020-00727-5"},{"issue":"1","key":"2734_CR62","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1038\/s41467-025-61149-7","volume":"16","author":"J Hou","year":"2025","unstructured":"Hou J, Zhao W, Nie Q. Dissecting crosstalk induced by cell-cell communication using single-cell transcriptomic data. Nat Commun. 2025;16(1):5970.","journal-title":"Nat Commun"},{"issue":"1","key":"2734_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, et al. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13\u201322.","journal-title":"Leukemia"},{"issue":"1","key":"2734_CR64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-016-0574-7","volume":"16","author":"X Wang","year":"2017","unstructured":"Wang X, Huang S, Chen J-L. Understanding of leukemic stem cells and their clinical implications. Mol Cancer. 2017;16(1):2.","journal-title":"Mol Cancer"},{"issue":"8","key":"2734_CR65","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","volume":"103","author":"GJ Roboz","year":"2018","unstructured":"Roboz GJ, et al. Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. 2018;103(8):1308\u201316.","journal-title":"Haematologica"},{"key":"2734_CR66","doi-asserted-by":"crossref","unstructured":"Aval OS, Ahmadi A, Hemid Al-Athari AJ, Soleimani Samarkhazan H, Sotudeh Chafi F, Asadi M, Mohammadi MH, Aghaei M. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann Hematol. 2025;9:1\u20134.","DOI":"10.1007\/s00277-025-06387-x"},{"key":"2734_CR67","doi-asserted-by":"crossref","unstructured":"Brodsk\u00e1 B, et al. High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations. Int J Mol Sci. 2019;20(11):2823.","DOI":"10.3390\/ijms20112823"},{"issue":"3","key":"2734_CR68","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, et al. Efficacy, Safety, and biomarkers of response to Azacitidine and nivolumab in Relapsed\/Refractory acute myeloid leukemia: A Nonrandomized, Open-Label, phase II study. Cancer Discov. 2019;9(3):370\u201383.","journal-title":"Cancer Discov"},{"key":"2734_CR69","doi-asserted-by":"crossref","unstructured":"Jimbu L, et al. Is there a place for PD-1-PD-L Blockade in acute myeloid leukemia? Pharmaceuticals (Basel). 2021;14(4):288.","DOI":"10.3390\/ph14040288"},{"issue":"15","key":"2734_CR70","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","volume":"41","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, et al. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study. J Clin Oncol. 2023;41(15):2815\u201326.","journal-title":"J Clin Oncol"},{"key":"2734_CR71","doi-asserted-by":"publisher","first-page":"1627161","DOI":"10.3389\/fimmu.2025.1627161","volume":"16","author":"M Liu","year":"2025","unstructured":"Liu M, et al. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025;16:1627161.","journal-title":"Front Immunol"},{"issue":"1","key":"2734_CR72","first-page":"6268514","volume":"2020","author":"M-H Bao","year":"2020","unstructured":"Bao M-H, et al. A novel putative role of TNK1 in atherosclerotic inflammation implicating the Tyk2\/STAT1 pathway. Mediat Inflamm. 2020;2020(1):6268514.","journal-title":"Mediat Inflamm"},{"issue":"12","key":"2734_CR73","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","volume":"187","author":"S Bandyopadhyay","year":"2024","unstructured":"Bandyopadhyay S, et al. Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell. 2024;187(12):3120\u2013e314029.","journal-title":"Cell"},{"key":"2734_CR74","doi-asserted-by":"crossref","unstructured":"Cooper R, et al. Spatial transcriptomic approaches for characterising the bone marrow landscape: pitfalls and potential. Leukemia. 2024;39:291\u201395.","DOI":"10.1038\/s41375-024-02480-8"},{"key":"2734_CR75","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood-2024-201932","volume":"144","author":"E Dasdemir","year":"2024","unstructured":"Dasdemir E, et al. Multimodal spatial transcriptomic profiling elucidates niche-specific dynamics in medullary and extramedullary acute myeloid leukemia. Blood. 2024;144:1059.","journal-title":"Blood"},{"key":"2734_CR76","doi-asserted-by":"publisher","first-page":"106873","DOI":"10.1016\/j.compbiomed.2023.106873","volume":"159","author":"M Zhu","year":"2023","unstructured":"Zhu M, et al. MLSpatial: a machine-learning method to reconstruct the spatial distribution of cells from scRNA-seq by extracting spatial features. Comput Biol Med. 2023;159:106873.","journal-title":"Comput Biol Med"},{"issue":"1","key":"2734_CR77","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12964-024-01877-3","volume":"22","author":"E Peroni","year":"2024","unstructured":"Peroni E, et al. Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology. Cell Communication Signal. 2024;22(1):510.","journal-title":"Cell Communication Signal"},{"key":"2734_CR78","doi-asserted-by":"crossref","unstructured":"Gui G, Bingham MA, Herzog JR, Wong-Rolle A, Dillon LW, Goswami M, Martin E, Reeves J, Kim S, Bahrami A, Degenhardt H. Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML. bioRxiv. [Pre-print] 2025 Jan 27.","DOI":"10.1101\/2025.01.24.634753"},{"issue":"1","key":"2734_CR79","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41698-025-00897-7","volume":"9","author":"CP Ly","year":"2025","unstructured":"Ly CP, et al. Multimodal spatial proteomic profiling in acute myeloid leukemia. NPJ Precision Oncol. 2025;9(1):148.","journal-title":"NPJ Precision Oncol"},{"key":"2734_CR80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14744\/ejmo.2023.35138","volume":"2023","author":"A Zahran","year":"2023","unstructured":"Zahran A, et al. Disturbed expression of memory T-Cell subsets could alter the outcomes in adult acute myeloid leukemia. Eurasian J Med Oncol. 2023;2023:362\u201370.","journal-title":"Eurasian J Med Oncol"},{"issue":"2","key":"2734_CR81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1042\/ETLS20210244","volume":"6","author":"Z Ahmed","year":"2022","unstructured":"Ahmed Z. Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities. Emerg Top Life Sci. 2022;6(2):215\u201325.","journal-title":"Emerg Top Life Sci"},{"issue":"6","key":"2734_CR82","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"RJ Arg\u00fcello","year":"2020","unstructured":"Arg\u00fcello RJ, et al. SCENITH: A flow Cytometry-Based method to functionally profile energy metabolism with Single-Cell resolution. Cell Metabol. 2020;32(6):1063\u2013e10757.","journal-title":"Cell Metabol"},{"key":"2734_CR83","doi-asserted-by":"crossref","unstructured":"Aghayan AH et al. Extracellular vesicle-based biomarkers in diffuse large B-cell lymphoma: s systematic review and meta-analysis. Crit Rev Oncol\/Hematol. 2025;215:104884.","DOI":"10.1016\/j.critrevonc.2025.104884"},{"key":"2734_CR84","doi-asserted-by":"crossref","unstructured":"Kubaev A, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res. 2025;35:1\u201311.","DOI":"10.1080\/08982104.2025.2495261"},{"issue":"1","key":"2734_CR85","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s11033-025-10971-9","volume":"52","author":"C Song","year":"2025","unstructured":"Song C, et al. An update on extracellular vesicles in hematologic disorders: molecular mediators, clinical biomarkers, and emerging therapeutics. Mol Biol Rep. 2025;52(1):868.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"2734_CR86","doi-asserted-by":"publisher","first-page":"2400363","DOI":"10.1002\/adtp.202400363","volume":"8","author":"B Wu","year":"2025","unstructured":"Wu B, et al. Dimethyl fumarate augments anticancer activity of \u00c5ngstrom silver particles in myeloma cells through NRF2 activation. Adv Ther. 2025;8(1):2400363.","journal-title":"Adv Ther"},{"issue":"7","key":"2734_CR87","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/1878-0261.13588","volume":"18","author":"FWM Verheijen","year":"2024","unstructured":"Verheijen FWM, et al. Deciphering metabolic crosstalk in context: lessons from inflammatory diseases. Mol Oncol. 2024;18(7):1759\u201376.","journal-title":"Mol Oncol"},{"issue":"6","key":"2734_CR88","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12032-025-02742-0","volume":"42","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cell-derived exosomes: a novel therapeutic frontier in hematological disorders. Med Oncol. 2025;42(6):199.","journal-title":"Med Oncol"},{"issue":"6","key":"2734_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00432-025-06244-4","volume":"151","author":"MJ Saadh","year":"2025","unstructured":"Saadh MJ, et al. Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML. J Cancer Res Clin Oncol. 2025;151(6):193.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2734_CR90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29(1):115\u201326.","journal-title":"Nat Med"},{"issue":"5","key":"2734_CR91","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/bloodadvances.2020003398","volume":"5","author":"CAC Peretz","year":"2021","unstructured":"Peretz CAC, et al. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Adv. 2021;5(5):1437\u201341.","journal-title":"Blood Adv"},{"key":"2734_CR92","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1182\/blood-2024-211634","volume":"144","author":"A Liu","year":"2024","unstructured":"Liu A, et al. Single-cell proteogenomic analysis of clonal evolution in patient-derived xenograft models of AML treated with IDH inhibitors. Blood. 2024;144:4995.","journal-title":"Blood"},{"issue":"1","key":"2734_CR93","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41467-021-22874-x","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang F, et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021;12(1):2607.","journal-title":"Nat Commun"},{"key":"2734_CR94","doi-asserted-by":"crossref","unstructured":"Bruno S, et al. Tracking response and resistance in acute myeloid leukemia through single-cell DNA sequencing helps uncover new therapeutic targets. Int J Mol Sci. 2024;25(18):10002.","DOI":"10.3390\/ijms251810002"},{"issue":"12","key":"2734_CR95","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1038\/s41588-024-01999-x","volume":"56","author":"A-M Lepp\u00e4","year":"2024","unstructured":"Lepp\u00e4 A-M, et al. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype. Nat Genet. 2024;56(12):2790\u2013803.","journal-title":"Nat Genet"},{"issue":"38","key":"2734_CR96","doi-asserted-by":"publisher","first-page":"eadg0488","DOI":"10.1126\/sciadv.adg0488","volume":"9","author":"TM Robinson","year":"2023","unstructured":"Robinson TM, et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023;9(38):eadg0488.","journal-title":"Sci Adv"},{"key":"2734_CR97","doi-asserted-by":"crossref","unstructured":"Zhang Y, et al. Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis. J Adv Res. 2025;80:487\u2013501.","DOI":"10.1016\/j.jare.2025.05.038"},{"issue":"4","key":"2734_CR98","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","volume":"122","author":"CC Bell","year":"2020","unstructured":"Bell CC, Gilan O. Principles and mechanisms of non-genetic resistance in cancer. Br J Cancer. 2020;122(4):465\u201372.","journal-title":"Br J Cancer"},{"issue":"22","key":"2734_CR99","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021;81(22):5589\u201395.","journal-title":"Cancer Res"},{"key":"2734_CR100","doi-asserted-by":"crossref","unstructured":"Shuai Y, Huang H. Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer. J Natl Cancer Cent. 2025;13:1\u201315.","DOI":"10.1016\/j.jncc.2025.06.001"},{"issue":"1","key":"2734_CR101","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s44313-024-00010-0","volume":"59","author":"YU Cho","year":"2024","unstructured":"Cho YU. The role of next-generation sequencing in hematologic malignancies. Blood Res. 2024;59(1):11.","journal-title":"Blood Res"},{"issue":"1","key":"2734_CR102","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12672-025-01816-9","volume":"16","author":"N Ghoreyshi","year":"2025","unstructured":"Ghoreyshi N, et al. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discover Oncol. 2025;16(1):578.","journal-title":"Discover Oncol"},{"issue":"4","key":"2734_CR103","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3343\/alm.2023.43.4.328","volume":"43","author":"JJ Kim","year":"2023","unstructured":"Kim JJ, et al. Development of a Next-generation Sequencing-based gene panel test to detect measurable residual disease in acute myeloid leukemia. Ann Lab Med. 2023;43(4):328\u201336.","journal-title":"Ann Lab Med"},{"issue":"1","key":"2734_CR104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-023-00833-7","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, et al. NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood Cancer J. 2023;13(1):59.","journal-title":"Blood Cancer J"},{"issue":"13","key":"2734_CR105","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189\u201399.","journal-title":"N Engl J Med"},{"key":"2734_CR106","doi-asserted-by":"publisher","first-page":"204062072513492","DOI":"10.1177\/20406207251349261","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. The clinical utility and prognostic value of next-generation sequencing for measurable residual disease assessment in acute myeloid leukemia. Ther Adv Hematol. 2025;16:20406207251349261.","journal-title":"Ther Adv Hematol"},{"issue":"13","key":"2734_CR107","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood.2023021815","volume":"143","author":"A Mathioudaki","year":"2024","unstructured":"Mathioudaki A, et al. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature. Blood. 2024;143(13):1269\u201381.","journal-title":"Blood"},{"key":"2734_CR108","doi-asserted-by":"publisher","first-page":"1114368","DOI":"10.3389\/fimmu.2023.1114368","volume":"14","author":"B Obermayer","year":"2023","unstructured":"Obermayer B, et al. Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2023;14:1114368.","journal-title":"Front Immunol"},{"issue":"1","key":"2734_CR109","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","volume":"14","author":"S Pagliuca","year":"2023","unstructured":"Pagliuca S, et al. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation. Nat Commun. 2023;14(1):3153.","journal-title":"Nat Commun"},{"issue":"7","key":"2734_CR110","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888. \u20131902.e21.","journal-title":"Cell"},{"issue":"4","key":"2734_CR111","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1158\/2643-3230.BCD-24-0342","volume":"6","author":"AGX Zeng","year":"2025","unstructured":"Zeng AGX, et al. Single-cell transcriptional atlas of human hematopoiesis reveals genetic and hierarchy-based determinants of aberrant AML differentiation. Blood Cancer Discov. 2025;6(4):307\u201324.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2734_CR112","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75(1):46\u201367.","journal-title":"CA Cancer J Clin"},{"issue":"Supplement 1","key":"2734_CR113","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1182\/blood-2024-207400","volume":"144","author":"K Micin","year":"2024","unstructured":"Micin K, et al. Clinical application of Single-Cell MRD by genotype and phenotype in AML. Blood. 2024;144(Supplement 1):4333\u20134333.","journal-title":"Blood"},{"issue":"38","key":"2734_CR114","doi-asserted-by":"publisher","first-page":"eadk2533","DOI":"10.1126\/sciadv.adk2533","volume":"9","author":"X Zhang","year":"2023","unstructured":"Zhang X, Grimes HL. Improved detection of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023;9(38):eadk2533.","journal-title":"Sci Adv"},{"key":"2734_CR115","doi-asserted-by":"publisher","first-page":"113392","DOI":"10.1016\/j.intimp.2024.113392","volume":"144","author":"D-Y Sun","year":"2025","unstructured":"Sun D-Y, et al. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol. 2025;144:113392.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2734_CR116","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/pharmaceutics16121582","volume":"16","author":"C Feng","year":"2024","unstructured":"Feng C, et al. Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect. Pharmaceutics. 2024;16(12):1582.","journal-title":"Pharmaceutics"},{"key":"2734_CR117","unstructured":"FDA approves Gemtuzumab Ozogamicin for CD33-positive AML. Food and Drug Administration; 2017."},{"key":"2734_CR118","unstructured":"Phase I Trial of CLEc12a (CD371) Targeted ArmoRed Immune Effector Cells in Patients With Relapsed\/Refractory Acute Myeloid Leukemia (CLEAR-AML). 2023."},{"key":"2734_CR119","doi-asserted-by":"crossref","unstructured":"Geyer\u2013 MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis, Z, Lorenc R, Lewis AM, Gipson B. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood, 2025;146(26):3163\u201374.","DOI":"10.1182\/blood.2025029532"},{"issue":"7","key":"2734_CR120","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.stem.2024.04.021","volume":"31","author":"S Li","year":"2024","unstructured":"Li S, et al. Modified lentiviral globin gene therapy for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia: a single-center, single-arm pilot trial. Cell Stem Cell. 2024;31(7):961\u2013e9738.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2734_CR121","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjh.19519","volume":"205","author":"WY Jen","year":"2024","unstructured":"Jen WY, et al. Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease. Br J Haematol. 2024;205(1):30\u201347.","journal-title":"Br J Haematol"},{"issue":"1","key":"2734_CR122","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Experimental Med. 2025;25(1):215.","journal-title":"Clin Experimental Med"},{"issue":"1","key":"2734_CR123","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Exp Med. 2025;25(1):240.","journal-title":"Clin Exp Med"},{"issue":"5","key":"2734_CR124","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3923\/ijp.2023.632.641","volume":"19","author":"Q Su","year":"2023","unstructured":"Su Q, et al. Dihydroartemisinin increases the sensitivity of acute myeloid leukemia cells to cytarabine via the Nrf2\/HO-1 anti-oxidant signaling pathway. IJP. 2023;19(5):632\u201341.","journal-title":"IJP"},{"key":"2734_CR125","doi-asserted-by":"crossref","unstructured":"Guo H-Z, et al. A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell Rep Med. 2024;5(6):1\u201325.","DOI":"10.1016\/j.xcrm.2024.101592"},{"issue":"12","key":"2734_CR126","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387.","journal-title":"Nat Cancer"},{"issue":"5","key":"2734_CR127","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41592-019-0392-0","volume":"16","author":"EP Mimitou","year":"2019","unstructured":"Mimitou EP, et al. Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells. Nat Methods. 2019;16(5):409\u201312.","journal-title":"Nat Methods"},{"issue":"9","key":"2734_CR128","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nmeth.4380","volume":"14","author":"M Stoeckius","year":"2017","unstructured":"Stoeckius M, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14(9):865\u20138.","journal-title":"Nat Methods"},{"issue":"1","key":"2734_CR129","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41467-021-21810-3","volume":"12","author":"B Demaree","year":"2021","unstructured":"Demaree B, et al. Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nat Commun. 2021;12(1):1583.","journal-title":"Nat Commun"},{"issue":"6","key":"2734_CR130","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nmeth.3370","volume":"12","author":"IC Macaulay","year":"2015","unstructured":"Macaulay IC, et al. G&T-seq: parallel sequencing of single-cell genomes and transcriptomes. Nat Methods. 2015;12(6):519\u201322.","journal-title":"Nat Methods"},{"issue":"3","key":"2734_CR131","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.xpro.2020.100125","volume":"1","author":"A Rodriguez-Meira","year":"2020","unstructured":"Rodriguez-Meira A, et al. TARGET-Seq: a protocol for High-Sensitivity Single-Cell mutational analysis and parallel RNA sequencing. STAR Protoc. 2020;1(3):100125.","journal-title":"STAR Protoc"},{"issue":"1","key":"2734_CR132","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s42003-023-04635-2","volume":"6","author":"MS Mansuri","year":"2023","unstructured":"Mansuri MS, Williams K, Nairn AC. Uncovering biology by single-cell proteomics. Commun Biology. 2023;6(1):381.","journal-title":"Commun Biology"},{"issue":"7","key":"2734_CR133","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/ijms25073828","volume":"25","author":"Y Xie","year":"2024","unstructured":"Xie Y, Chen H, Chellamuthu VR, Lajam ABM, Albani S, Low AHL, Petretto E, Behmoaras J. Comparative analysis of single-cell RNA sequencing methods with and without sample multiplexing. Int J Mol Sci. 2024;25(7):3828.","journal-title":"Int J Mol Sci"},{"key":"2734_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42256-024-00868-w","volume":"6","author":"R Jiang","year":"2024","unstructured":"Jiang R, et al. A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas. Nat Mach Intell. 2024;6:1\u201316.","journal-title":"Nat Mach Intell"},{"issue":"4","key":"2734_CR135","doi-asserted-by":"publisher","first-page":"e70218","DOI":"10.1002\/jbt.70218","volume":"39","author":"RO Saleh","year":"2025","unstructured":"Saleh RO, et al. Single-cell RNA sequencing contributes to the treatment of acute myeloid leukaemia with hematopoietic stem cell transplantation, chemotherapy, and immunotherapy. J Biochem Mol Toxicol. 2025;39(4):e70218.","journal-title":"J Biochem Mol Toxicol"},{"issue":"4","key":"2734_CR136","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jtho.2021.01.1616","volume":"16","author":"FS Ou","year":"2021","unstructured":"Ou FS, et al. Biomarker discovery and validation: statistical considerations. J Thorac Oncol. 2021;16(4):537\u201345.","journal-title":"J Thorac Oncol"},{"key":"2734_CR137","unstructured":"Biomarker qualification: evidentiary framework. Food and Drug Administration; 2020."},{"key":"2734_CR138","unstructured":"Single-cell sequencing and establishment of cell Lines, Organoids, and transplanted tumor models in neuroendocrine neoplasm. L.C. D1 Medical Technology Co, editor. 2021."},{"issue":"1","key":"2734_CR139","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1038\/s41467-024-52980-5","volume":"15","author":"A Ianevski","year":"2024","unstructured":"Ianevski A, et al. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones. Nat Commun. 2024;15(1):8579.","journal-title":"Nat Commun"},{"issue":"1","key":"2734_CR140","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41417-023-00691-2","volume":"31","author":"S Qu","year":"2024","unstructured":"Qu S, et al. Research progress and application of single-cell sequencing in head and neck malignant tumors. Cancer Gene Ther. 2024;31(1):18\u201327.","journal-title":"Cancer Gene Ther"},{"issue":"02","key":"2734_CR141","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1042\/EBC20253017","volume":"69","author":"W Zhou","year":"2025","unstructured":"Zhou W, et al. Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy. Essays Biochem. 2025;69(02):77\u201395.","journal-title":"Essays Biochem"},{"issue":"1","key":"2734_CR142","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1182\/hematology.2024000588","volume":"2024","author":"G Orofino","year":"2024","unstructured":"Orofino G, Vago L. Biology of post-transplant relapse: actionable features. Hematology. 2024;2024(1):736\u201343.","journal-title":"Hematology"},{"issue":"3","key":"2734_CR143","doi-asserted-by":"publisher","first-page":"qiae229","DOI":"10.1093\/jleuko\/qiae229","volume":"117","author":"F Martins","year":"2025","unstructured":"Martins F, et al. Single-cell transcriptome analysis reveals atypical monocytes Circulating ahead of acute graft-versus-host disease clinical onset. J Leukoc Biol. 2025;117(3):qiae229.","journal-title":"J Leukoc Biol"},{"key":"2734_CR144","doi-asserted-by":"crossref","unstructured":"Mathews JA, et al. Single cell profiling of hematopoietic stem cell transplant recipients reveals TGF-\u03b21 and IL-2 confer immunoregulatory functions to NK cells. iScience. 2024;27(12):111416.","DOI":"10.1016\/j.isci.2024.111416"},{"key":"2734_CR145","volume-title":"Performance of the tapestri platform for single-cell targeted DNA sequencing","author":"M Bio","year":"2019","unstructured":"Bio M. Performance of the tapestri platform for single-cell targeted DNA sequencing. Mission: Bio; 2019."},{"issue":"1","key":"2734_CR146","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s42003-025-08316-0","volume":"8","author":"H Wang","year":"2025","unstructured":"Wang H, He X, Ma M, Dou T, Wei Y, Rux D, Qin L, Yang Y, Zhu Y, Yao L. Integrating spatial and single-cell transcriptomics to characterize mouse long bone fracture healing process. Commun Biology. 2025;8(1):887.","journal-title":"Commun Biology"},{"key":"2734_CR147","doi-asserted-by":"crossref","unstructured":"Sudupe L, Mui\u00f1os-Lopez E, Lopez-Perez AR, Vilas-Zornoza A, Sarvide S, Ripalda-Cemborain P, Aguirre-Ruiz P, San Martin-Uriz P, Larrayoz M, Alvarez-Gigli L, Abengozar-Muela M. Bone marrow spatial transcriptomics reveals a myeloma cell architecture with dysfunctional T-cell distribution, neutrophil traps, and inflammatory signaling. BioRxiv [Pre-print]. 2024;2024\u201307.","DOI":"10.1101\/2024.07.03.601833"},{"issue":"1","key":"2734_CR148","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12864-020-07358-4","volume":"22","author":"TM Yamawaki","year":"2021","unstructured":"Yamawaki TM, et al. Systematic comparison of high-throughput single-cell RNA-seq methods for immune cell profiling. BMC Genomics. 2021;22(1):66.","journal-title":"BMC Genomics"},{"key":"2734_CR149","doi-asserted-by":"crossref","unstructured":"De Simone M, et al. A comprehensive analysis framework for evaluating commercial single-cell RNA sequencing technologies. Nucleic Acids Res. 2025;53(2):gkae1186.","DOI":"10.1093\/nar\/gkae1186"},{"issue":"6","key":"2734_CR150","first-page":"1269","volume":"110","author":"YJ Kim","year":"2025","unstructured":"Kim YJ, Takahashi K. Emerging technologies of single-cell multi-omics. Haematologica. 2025;110(6):1269\u201377.","journal-title":"Haematologica"},{"issue":"9","key":"2734_CR151","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41587-020-00748-9","volume":"39","author":"W Chen","year":"2021","unstructured":"Chen W, et al. A multicenter study benchmarking single-cell RNA sequencing technologies using reference samples. Nat Biotechnol. 2021;39(9):1103\u201314.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2734_CR152","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41587-020-00744-z","volume":"38","author":"A F\u00fcllgrabe","year":"2020","unstructured":"F\u00fcllgrabe A, et al. Guidelines for reporting single-cell RNA-seq experiments. Nat Biotechnol. 2020;38(12):1384\u20136.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2734_CR153","doi-asserted-by":"publisher","first-page":"e8746","DOI":"10.15252\/msb.20188746","volume":"15","author":"MD Luecken","year":"2019","unstructured":"Luecken MD, Theis FJ. Current best practices in single-cell RNA-seq analysis: a tutorial. Mol Syst Biol. 2019;15(6):e8746.","journal-title":"Mol Syst Biol"},{"key":"2734_CR154","doi-asserted-by":"crossref","unstructured":"Ma D, et al. Beyond biomarkers: machine learning-driven multiomics for personalized medicine in gastric cancer. J Pers Med. 2025;15(5):166.","DOI":"10.3390\/jpm15050166"},{"key":"2734_CR155","unstructured":"Prasad Lakshmanan SS. Beyond ELISA: the future of biomarker validation. Drug Target Rev. 2024;27:1\u20133."},{"key":"2734_CR156","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41587-020-0469-4","volume":"38","author":"E Mereu","year":"2020","unstructured":"Mereu E, et al. Benchmarking single-cell RNA-sequencing protocols for cell atlas projects. Nat Biotechnol. 2020;38:747\u201355.","journal-title":"Nat Biotechnol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02734-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:02:08Z","timestamp":1774476128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02734-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2734"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02734-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}